PLx Pharma Winddown Corp. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2016 to 2021
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
PLx Pharma Winddown Corp. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2016 to 2021.
- PLx Pharma Winddown Corp. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2022 was -$8.5M, a 60.7% increase year-over-year.
- PLx Pharma Winddown Corp. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending September 30, 2022 was -$27.6M, a 52.2% increase year-over-year.
- PLx Pharma Winddown Corp. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$46.1M, a 203% decline from 2020.
- PLx Pharma Winddown Corp. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$15.2M, a 25.8% increase from 2019.
- PLx Pharma Winddown Corp. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2019 was -$20.5M, a 2387% decline from 2018.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)